Intensity Therapeutics in the News

Intensity Rings the Nasdaq Stock Market Closing Bell

On December 28, the team from Intensity Therapeutics visited the Nasdaq MarketSite in New York's Times Square. In honor of the occasion, Lewis H. Bender, ...
read more

Video: Dr. Angel Arnaout of Ottawa Hospital describing the ASCO 2022 INVINCIBLE study results

Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research Program at The Ottawa Hospital. ...
read more

Video: Dr. Matthew Ingham discusses the use of INT230-6 in sarcoma presented at the CTOS meeting 2021

Matthew A. Ingham, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Columbia University Vagelos College of Physicians and Surgeons speaks ...
read more

Killing Cancer Through Direct Injection

Intensity Therapeutics founder and the inventor of Intensity’s DfuseRx platform technology, Lew Bender, discusses the technology that allows the company’s therapeutic products to be injected ...
read more

BioBoss Interview of Intensity’s CEO Lewis H. Bender

BioBoss host John Simboli interviewed Intensity Therapeutics’ CEO, Lewis H. Bender in March of 2020. The two discussed the challenges facing a small company developing ...
read more

Clinical Leader: How One Small Biotech is Changing the Fight Against Cancer

Intensity Therapeutics would like to change the way cancer patients are treated. Treatments such as chemotherapy and radiation impact a patient’s entire body, administering toxic ...
read more

Combining Local & Systemic Treatments: Could Immuno-Oncology Finally Enable Local Intratumoral Delivery?

In an interview with Drug Development and Delivery, Lewis H. Bender, MA, MBA, says cancer is a local and systemic disease, and new forms of ...
read more

Lewis Bender Started a Company to Cure Cancer

Lewis Bender, CEO of a Connecticut startup called Intensity Therapeutics, feels compelled to cure cancer. “I had friends dying of cancer when I was in ...
read more

PharmaVOICE Names Intensity Therapeutics’ CEO, Lewis H. Bender, One of 100 Most Inspiring People for 2019

[pdf-embedder url=”https://intensitytherapeutics.com/wp-content/uploads/2019/08/PharmaVOICE-finished-article.pdf” title=”PharmaVOICE finished ...
read more

ForbesBooks Radio: Lewis H. Bender, Founder/CEO, talks Intensity Therapeutics

Starting in his basement, Lew and his team have created unique cancer penetrating drugs that kill tumors and boost immunity via direct injection, with minimal ...
read more

A Treat Locally, Act Globally Strategy for Treating Cancer

Intensity is developing cancer therapies that are delivered directly into tumors, but also stimulate the innate immune system to address the more systemic effects of ...
read more

Tuning In: Intensity’s immune-based chemo delivery tech attracts backing of British billionaire Jim Mellon

In cancer treatment, chemotherapy and immunotherapy are often seen as completely separate, if complementary, categories of treatments. A tiny biotech out of Westport, CT now ...
read more

Westport Biotech Venture Aims to Make a Cancer Cure that Lasts

A Westport biotechnology company is looking to redefine what it means to be cured of cancer, developing a treatment that essentially trains the immune system ...
read more

Westport’s Intensity Therapeutics optimistic about potential cancer treatment

Westport’s Intensity Therapeutics gains ground with potential game changing cancer treatment. Armed with a pair of U.S. patents and some $13 million in investments, Intensity ...
read more

Intensity Therapeutics Begins Human Testing of Intratumoral Cancer Drug

Intensity Therapeutics said today that the 1st patient was treated in a Phase I/II trial of its intratumorally-administered cancer therapy, INT230-6. The company’s plans to ...
read more

Intensity Therapeutics Inc. – Delivering Improved Immunotherapy

Intensity Therapeutics Inc. got its start when Lewis H. Bender, then the CEO of Interleukin Genetics Inc., pondered the treatment failures in checkpoint inhibitors. “I ...
read more

Throwing Cancer a One-Two Combo

Many cancer treatments have achieved cures in mice only to fail in humans. Intensity Therapeutics has studied these failed challengers, and it may have learned ...
read more

Chicago venture investor Batterson eyes crowdfunding for cancer treatment

Venture investor Len Batterson says new crowdfunding rules will widen the pool of sophisticated investors, too.
read more

Intensity Therapeutics Looks to Raise USD 7.5m to Bring Intratumoral Chemo to Clinical Trials

Intensity Therapeutics has raised USD 1.5m of its planned USD 9m target for its lead preclinical candidate, an intratumoral chemotherapy, said CEO Lewis Bender. By ...
read more

Intensity: More with Less

Intensity Therapeutics Inc. is developing what could become the first intratumoral chemotherapeutics to achieve better efficacy than systemic chemo by using a formulation technology that ...
read more